Browsing Category
COVID-19
A coronavirus-mimic mesoporous silica nanosystem enables efficient targeted delivery of siRNA for…
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a threat to human beings' health. However, there is still a lack of effective specific antiviral drugs for SARS-CoV-2 at present, which calls for the exploitation of new potent and safe therapeutic agents.…
Read More...
Read More...
The R&D landscape for infectious disease vaccines
Vaccines have a tremendous impact on public health, and their importance has been emphasized by the COVID-19 pandemic. Here, we provide an overview of the current state of research and development (R&D) on prophylactic vaccine candidates for infectious diseases globally.
Technology platforms…
Read More...
Read More...
Active ingredient vs excipient debate for nanomedicines
Nanomedicines are complex drugs where components that have typically been regarded as excipients may now be considered part of the active ingredient. The distinction between the active ingredient and excipients for nanomedicines has important consequences for regulatory review and product…
Read More...
Read More...
Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines
Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms…
Read More...
Read More...
Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation
Neutralising monoclonal antibody (mAb) is an important weapon in our arsenal for combating respiratory viral infections. However, the effectiveness of neutralising mAb has been impeded by the rapid emergence of mutant variants. Early administration of broad-spectrum mAb with improved delivery…
Read More...
Read More...
Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures
Messenger RNA (mRNA) lipid nanoparticles (LNPs) have emerged at the forefront during the COVID-19 vaccination campaign. Despite their tremendous success, mRNA vaccines currently require storage at deep freeze temperatures which complicates their storage and distribution, and ultimately leads to…
Read More...
Read More...
The Role of Cyclodextrins in COVID-19 Therapy—A Literature Review
Coronavirus disease-19 (COVID-19) emerged in December 2019 and quickly spread, giving rise to a pandemic crisis. Therefore, it triggered tireless efforts to identify the mechanisms of the disease, how to prevent and treat it, and to limit and hamper its global dissemination. Considering the above,…
Read More...
Read More...
Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery
Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicles for RNA and have enabled the development of RNA-based drugs such as the mRNA COVID-19 vaccines. Functional delivery of mRNA by an LNP greatly depends on the inclusion of an ionizable lipid, and small changes to these lipid…
Read More...
Read More...
SARS-CoV-2 vaccine excipients polyethylene glycol and trometamol do not induce mast cell…
The development of vaccines against SARS-CoV2 brought about several challenges, including the management of hypersensitivity reactions to these formulations. The search for underlying mechanisms involved in these adverse events initially focused on excipients which may trigger mast cell activation…
Read More...
Read More...
Microcrystalline cellulose promotes superior direct compressed Boesenbergia rotunda (L.) Mansf.…
This work aimed to select tablet diluent of Boesenbergia rotunda (L.) Mansf. extract tablet. Three tablet diluents, including microcrystalline cellulose (MCC), spray-dried rice starch, and spray-dried lactose were used. MCC exhibited superior performance to the other diluents by providing the…
Read More...
Read More...